dostarlimab,pembrolizumab
gsk,merck
['perla trial']
different pd-(l)1 inhibitors are often thought to have similar to identical clinical efficacy and safety. do they? first trial with a head to head comparison presented by at #esmoimmuno22 
Oncology fellow @DanaFarber @MGHCancerCenter | @BMCimRES alum | #hereditarycancer #tumorimmunology #immunotherapy | Language aficionado | Views mine | he/him